Nurix Therapeutics Gets FDA Fast-Track Designation for NX-5948
17 January 2024 - 8:48AM
Dow Jones News
By Sabela Ojea
Nurix Therapeutics said the Food and Drug Administration has
granted fast-track designation for NX-5948, its treatment for
certain types of lymphocytic cancer.
NX-5948 is a degrader of Bruton's tyrosine kinase and is being
studied to treat relapsed or refractory chronic lymphocytic
leukemia or small lymphocytic lymphoma.
The clinical-stage biopharmaceutical company on Tuesday said the
designation follows encouraging safety and efficacy data from its
ongoing Phase 1 clinical trial.
The FDA's fast-track designation is aimed at facilitating and
expediting the development and review of drug candidates.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 16, 2024 16:33 ET (21:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Apr 2024 to May 2024
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From May 2023 to May 2024
